Oncomine comprehensive assay v3 ocav3

Available molecular sequencing data were compiled from the pathology records, including SNV, small insertions/deletions (indel), copy number variants (CNV) and structural rearrangements. The sequencing was previously performed on formalinfixed paraffin-embedded pathology samples using the Oncomine Comprehensive Assay v3 (OCAv3) (Thermo Fisher Scientific), a targeted panel covering 161 cancer-associated genes and currently used in our routine clinical setting. 29 (link) In brief, DNA and RNA were extracted simultaneously using RecoverAll Total Nucleic Acid Isolation Kit (Thermo Fisher Scientific, USA). The quantity of the extracted DNA and RNA samples was measured on a Qubit 3.0 Fluorometer and adjusted to 20 ng and

All patients with solid malignancies included in this retrospective single-center study were presented in the molecular tumor board at the Comprehensive Cancer Center München-LMU (CCCM LMU ). In 2019, in-house diagnostics were changed to a 161-gene panel (Oncomine™ Comprehensive Assay v3 (OCAv3), ThermoFisher Scientific) and the Oncomine Tumor Mutational Load Assay (ThermoFisher Scientific) was added to the diagnostic repertoire [22] . For the present analysis, we only included patients that received the 161-gene panel and Tumor Mutational Analysis. Inclusion criteria was current cross-sectional imaging within the clinical routine no longer than three months prior to case presentation in the MTB. The study was conducted in accordance with the principles of the Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines. All patients gave written informed consent, and the study protocol was approved by the Ethics Committee of the medical faculty of the Ludwig Maximilians University Munich. Furthermore, all molecular diagnostic tests were conducted in accordance with the medical treatment contract signed by each patient.